Literature DB >> 1347195

Assignment of a gene (NEMI) for autosomal dominant nemaline myopathy to chromosome I.

N G Laing1, B T Majda, P A Akkari, M G Layton, J C Mulley, H Phillips, E A Haan, S J White, A H Beggs, L M Kunkel.   

Abstract

Nemaline myopathy (NEM) is a neuromuscular disorder characterized by the presence, in skeletal muscle, of nemaline rods composed at least in part of alpha-actinin. A candidate gene and linkage approach was used to localize the gene (NEM1) for an autosomal dominant form (MIM 161800) in one large kindred with 10 living affected family members. Markers on chromosome 19 that were linked to the central core disease gene, a marker at the complement 3 locus, and a marker on chromosome 1 at the alpha-actinin locus exclude these three candidate genes. The family was fully informative for APOA2, which is localized to 1q21-q23. NEM1 was assigned to chromosome 1 by close linkage for APOA2, which is localized to 1q21-q23. NEM1 was assigned to chromosome 1 by close linkage to APOA2, with a lod score of 3.8 at a recombination fraction of 0. Recombinants with NGFB (1p13) and AT3 (1q23-25.1) indicate that NEM1 lies between 1p13 and 1q25.1. In total, 47 loci were investigated on chromosomes 1, 2, 4, 5, 7-11, 14, 16, 17, and 19, with no indications of significant linkage other than to markers on chromosome 1.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347195      PMCID: PMC1684287     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  19 in total

1.  NEMALINE MYOPATHY. A NEW CONGENITAL MYOPATHY.

Authors:  G M SHY; W K ENGEL; J E SOMERS; T WANKO
Journal:  Brain       Date:  1963-12       Impact factor: 13.501

2.  The CEPH consortium linkage map of human chromosome 1.

Authors:  N C Dracopoli; P O'Connell; T I Elsner; J M Lalouel; R L White; K H Buetow; D Y Nishimura; J C Murray; C Helms; S K Mishra
Journal:  Genomics       Date:  1991-04       Impact factor: 5.736

Review 3.  Hereditary motor and sensory neuropathies.

Authors:  J M Vance
Journal:  J Med Genet       Date:  1991-01       Impact factor: 6.318

4.  Variable number of tandem repeat (VNTR) markers for human gene mapping.

Authors:  Y Nakamura; M Leppert; P O'Connell; R Wolff; T Holm; M Culver; C Martin; E Fujimoto; M Hoff; E Kumlin
Journal:  Science       Date:  1987-03-27       Impact factor: 47.728

5.  An exclusion map for facioscapulohumeral (Landouzy-Déjérine) disease.

Authors:  M Sarfarazi; M Upadhyaya; G Padberg; M Pericak-Vance; T Siddique; G Lucotte; P Lunt
Journal:  J Med Genet       Date:  1989-08       Impact factor: 6.318

6.  Human antithrombin II (AT3) gene length polymorphism revealed by the polymerase chain reaction.

Authors:  S Wu; S Seino; G I Bell
Journal:  Nucleic Acids Res       Date:  1989-08-11       Impact factor: 16.971

7.  Exclusion mapping.

Authors:  J H Edwards
Journal:  J Med Genet       Date:  1987-09       Impact factor: 6.318

8.  Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction.

Authors:  J L Weber; P E May
Journal:  Am J Hum Genet       Date:  1989-03       Impact factor: 11.025

9.  Congenital nemaline myopathy. I. Defective organization of alpha-actinin is restricted to muscle.

Authors:  F G Jennekens; J J Roord; H Veldman; J Willemse; B M Jockusch
Journal:  Muscle Nerve       Date:  1983-01       Impact factor: 3.217

10.  An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.

Authors:  A P Monaco; C J Bertelson; S Liechti-Gallati; H Moser; L M Kunkel
Journal:  Genomics       Date:  1988-01       Impact factor: 5.736

View more
  10 in total

Review 1.  Nemaline myopathy: current concepts. The ENMC International Consortium and Nemaline Myopathy.

Authors:  K N North; N G Laing; C Wallgren-Pettersson
Journal:  J Med Genet       Date:  1997-09       Impact factor: 6.318

Review 2.  Investigation of muscle disease.

Authors:  F L Mastaglia; N G Laing
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-03       Impact factor: 10.154

3.  Exclusion of two candidate loci for autosomal recessive nemaline myopathy.

Authors:  E Tahvanainen; A H Beggs; C Wallgren-Pettersson
Journal:  J Med Genet       Date:  1994-01       Impact factor: 6.318

4.  Changes in cross-bridge cycling underlie muscle weakness in patients with tropomyosin 3-based myopathy.

Authors:  Coen A C Ottenheijm; Michael W Lawlor; Ger J M Stienen; Henk Granzier; Alan H Beggs
Journal:  Hum Mol Genet       Date:  2011-02-28       Impact factor: 6.150

5.  Mutations of tropomyosin 3 (TPM3) are common and associated with type 1 myofiber hypotrophy in congenital fiber type disproportion.

Authors:  Michael W Lawlor; Elizabeth T Dechene; Emily Roumm; Amelia S Geggel; Behzad Moghadaszadeh; Alan H Beggs
Journal:  Hum Mutat       Date:  2010-02       Impact factor: 4.878

Review 6.  Distal myopathies.

Authors:  Mazen M Dimachkie; Richard J Barohn
Journal:  Neurol Clin       Date:  2014-05-15       Impact factor: 3.806

7.  Nemaline myopathy: two autopsy reports.

Authors:  M Bergmann; M Kamarampaka; K Kuchelmeister; H Klein; H Koch
Journal:  Childs Nerv Syst       Date:  1995-10       Impact factor: 1.475

8.  Approach to the diagnosis of congenital myopathies.

Authors:  Kathryn N North; Ching H Wang; Nigel Clarke; Heinz Jungbluth; Mariz Vainzof; James J Dowling; Kimberly Amburgey; Susana Quijano-Roy; Alan H Beggs; Caroline Sewry; Nigel G Laing; Carsten G Bönnemann
Journal:  Neuromuscul Disord       Date:  2013-11-18       Impact factor: 4.296

9.  The sarcomeric protein nebulin: another multifunctional giant in charge of muscle strength optimization.

Authors:  Coen A C Ottenheijm; Henk Granzier; Siegfried Labeit
Journal:  Front Physiol       Date:  2012-02-27       Impact factor: 4.566

10.  Nemaline Myopathy in Brazilian Patients: Molecular and Clinical Characterization.

Authors:  Juliana Gurgel-Giannetti; Lucas Santos Souza; Guilherme L Yamamoto; Marina Belisario; Monize Lazar; Wilson Campos; Rita de Cassia M Pavanello; Mayana Zatz; Umbertina Reed; Edmar Zanoteli; Acary Bulle Oliveira; Vilma-Lotta Lehtokari; Erasmo B Casella; Marcela C Machado-Costa; Carina Wallgren-Pettersson; Nigel G Laing; Vincenzo Nigro; Mariz Vainzof
Journal:  Int J Mol Sci       Date:  2022-10-09       Impact factor: 6.208

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.